LSL Web-Exclusive Content

  1. Stand And Deliver: Practical Steps To Stop Antibiotic Resistance

    For antibiotics, we need more investments in basic science, drug discovery, and clinical development. The big risk now is that the market for new antibiotics is absent as any incentive to invest in new medicines fades when their sole purpose would be to be used only exceptionally.

  2. An Industry On The Brink Of Radical Reinvention

    Accenture’s 2017 Technology Vision for Life Sciences examines how major technology trends are shaping the industry and provides recommendations for life sciences companies on how best to take advantage. Across the five trends we uncovered, the unifying theme was how technology is empowering patients and consumers, while driving business results:

  3. Three Steps to a More Resilient Organization

    Your leadership is the key to keeping your workforce focused, productive, optimistic, and creative no matter what comes your way. Here are three keys to building resilience in today’s dynamic healthcare universe.

  4. End Of A Humira Battle: Observations From The AbbVie-Amgen Armistice

    The recent settlement of the patent war involving Amgen’s biosimilar to AbbVie’s Humira (adalimumab) has caused rippling in the pharmaceutical industry. The companies had been battling worldwide since at least as early as August 2016, when AbbVie filed a lawsuit against Amgen in the U.S. District Court for the District of Delaware.

  5. Rare Diseases Require Unique Approaches In Clinical Trial Design

    The vast majority of rare diseases have no approved treatments available, despite the fact that research related to these diseases has expanded significantly in the past 20 years. A key reason may be the many unique challenges researchers face when developing drugs to treat rare diseases, including difficulties designing and executing effective and appropriate clinical trials.

  6. Are These 3 Fear Factors Holding You Back From Regulatory Compliance?

    In the TV series Fear Factor, contestants had to overcome various challenges that most of us found disgusting and/or frightening in order to win a large cash prize. If they failed, their hopes were gone and the contest ended for them. The same can be true for the pharmaceutical industry in trying to achieve the “prize” of being found compliant when audited.

  7. FDA Draft Guidance On Electronic Records And Signatures: The Next Chapter

    The FDA has released a Draft Guidance titled Use of Electronic Records and Electronic Signatures in Clinical Investigations Under 21 CFR Part 11 – Questions and Answers. Certainly, the development of this draft guidance was driven by the repetitious questions the FDA has received from industry stakeholders as well as the extensive technology advancements.

  8. How Amazon Could Disrupt The CRO Model

    Based on Amazon's approach to building its business, it is logical to conclude that the online retailer would be an amazing CRO. Amazon’s competitive strategy is to aggressively discount prices to win market share. Plus, its customer obsession and disruptive innovation are second to none. Let’s imagine what an Amazon-run CRO would look like.

  9. What Is Biopharma Innovation, Anyway? Italy’s New Algorithm & The Global Trend

    Although the term “innovative” implies some superior properties — perhaps worthy of premium price and increased use — there is little consensus among differing stakeholders as to what constitutes a true pharmaceutical innovation. 

  10. U.S. CEOs See Greater Willingness To Use Artificial Intelligence: KPMG Survey

    According to KPMG’s 2017 CEO Outlook, more than two-thirds of U.S. life sciences CEOs say their organizations are ready to adopt advanced artificial intelligence (AI) technology, but they acknowledge there are barriers to implementing it.